trending Market Intelligence /marketintelligence/en/news-insights/trending/_QamjJ9IsVdzh5u_xlK8bg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Evrofarma swings to profit in Q1


ESG hits the mainstream for European private equity sponsors


What’s the Bottom Line: Credit Impact of COVID-19 on US Municipals


Banking Essentials Newsletter - February Edition, Part 2


Episode 1: Origins of 451 Research - Part 1

Evrofarma swings to profit in Q1

Evrofarma SA said its normalized net income for the first quarter came to €296,250, compared with a loss of €103,130 in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin increased to 4.4% from negative 1.8% in the year-earlier period.

Total revenue rose 17.1% on an annual basis to €6.7 million from €5.7 million, and total operating expenses increased 5.7% year over year to €5.9 million from €5.6 million.

Reported net income totaled €218,000, or 2 cents per share, compared to a loss of €261,000, or a loss of 2 cents per share, in the year-earlier period.